Allogene's ALLO-316 Obtains FDA's RMAT Designation for Advanced Renal Cell Carcinoma

MT Newswires Live

Oct 29, 2024

Allogene Therapeutics (ALLO) said Tuesday that the US Food and Drug Administration has granted Regenerative Medicine Advanced Therapy, or RMAT, designation to its allogeneic CAR T candidate, ALLO-316, for treating adult patients with a type of advanced renal cell carcinoma.

The designation follows data from a phase 1 trial showing potential benefits for patients who have not responded to standard therapies, Allogene Therapeutics said. The ongoing trial is evaluating the safety and efficacy of ALLO-316, supported by Allogene's Dagger technology for enhanced CAR T cell expansion in solid tumors.

The RMAT designation aims to expedite the development and review process of ALLO-316, the company said.

Allogene shares rose 6.5% in recent trading.

Price: 2.86, Change: +0.18, Percent Change: +6.53

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2479280422"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2479280422\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2479280422?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-29 23:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479280422","market":"fut","top_or_hot":-1,"title":"Allogene's ALLO-316 Obtains FDA's RMAT Designation for Advanced Renal Cell Carcinoma","media":"MT Newswires Live","content":"<html><body><p> Allogene <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ALLO) said Tuesday that the US Food and Drug Administration has granted Regenerative Medicine Advanced Therapy, or RMAT, designation to its allogeneic CAR T candidate, ALLO-316, for treating adult patients with a type of advanced renal cell carcinoma.</p><p>The designation follows data from a phase 1 trial showing potential benefits for patients who have not responded to standard therapies, Allogene Therapeutics said. The ongoing trial is evaluating the safety and efficacy of ALLO-316, supported by Allogene's Dagger technology for enhanced CAR T cell expansion in solid tumors.</p><p>The RMAT designation aims to expedite the development and review process of ALLO-316, the company said.</p><p>Allogene shares rose 6.5% in recent trading.</p><p>Price: 2.86, Change: +0.18, Percent Change: +6.53</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allogene's ALLO-316 Obtains FDA's RMAT Designation for Advanced Renal Cell Carcinoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllogene's ALLO-316 Obtains FDA's RMAT Designation for Advanced Renal Cell Carcinoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-10-29 23:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Allogene <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ALLO) said Tuesday that the US Food and Drug Administration has granted Regenerative Medicine Advanced Therapy, or RMAT, designation to its allogeneic CAR T candidate, ALLO-316, for treating adult patients with a type of advanced renal cell carcinoma.</p><p>The designation follows data from a phase 1 trial showing potential benefits for patients who have not responded to standard therapies, Allogene Therapeutics said. The ongoing trial is evaluating the safety and efficacy of ALLO-316, supported by Allogene's Dagger technology for enhanced CAR T cell expansion in solid tumors.</p><p>The RMAT designation aims to expedite the development and review process of ALLO-316, the company said.</p><p>Allogene shares rose 6.5% in recent trading.</p><p>Price: 2.86, Change: +0.18, Percent Change: +6.53</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B7SZL793.SGD","symbol_name":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2479280422","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479280422","pubTimestamp":1730216034,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Allogene Therapeutics  said Tuesday that the US Food and Drug Administration has granted Regenerative Medicine Advanced Therapy, or RMAT, designation to its allogeneic CAR T candidate, ALLO-316, for treating adult patients with a type of advanced renal cell carcinoma.The designation follows data from a phase 1 trial showing potential benefits for patients who have not responded to standard therapies, Allogene Therapeutics said. The ongoing trial is evaluating the safety and efficacy of ALLO-316, supported by Allogene's Dagger technology for enhanced CAR T cell expansion in solid tumors.The RMAT designation aims to expedite the development and review process of ALLO-316, the company said.Allogene shares rose 6.5% in recent trading.Price: 2.86, Change: +0.18, Percent Change: +6.53","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B7SZL793.SGD":"Legg Mason Royce - US Small Cap Opportunity A Acc SGD-H","IE00B66KJ199.SGD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY  \" A\" (SGD) ACC","BK4505":"高瓴资本持仓","ALLO":"Allogene Therapeutics Inc.","BK4157":"电子设备和仪器","BLZ.SI":"爱文思控股","BK4139":"生物科技","IE0031619046.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) INC","AEIS":"先进能源工业公司","BK6522":"化石燃料股","IE00B19Z4B17.USD":"LEGG MASON ROYCE US SMALL CAP OPPORTUNITY \"A\" (USD) ACC","BK6088":"石油天然气设备与服务"},"translate_title":"Allogene的ALLO-316获得FDA晚期肾细胞癌RMAT认定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALLO":1,"BLZ.SI":1,"AEIS":1},"content_text":"Allogene Therapeutics (ALLO) said Tuesday that the US Food and Drug Administration has granted Regenerative Medicine Advanced Therapy, or RMAT, designation to its allogeneic CAR T candidate, ALLO-316, for treating adult patients with a type of advanced renal cell carcinoma.The designation follows data from a phase 1 trial showing potential benefits for patients who have not responded to standard therapies, Allogene Therapeutics said. The ongoing trial is evaluating the safety and efficacy of ALLO-316, supported by Allogene's Dagger technology for enhanced CAR T cell expansion in solid tumors.The RMAT designation aims to expedite the development and review process of ALLO-316, the company said.Allogene shares rose 6.5% in recent trading.Price: 2.86, Change: +0.18, Percent Change: +6.53","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}